177 related articles for article (PubMed ID: 17529899)
21. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium.
Ortega F; Sánchez-Fructuoso A; Cruzado JM; Gómez-Alamillo JC; Alarcón A; Pallardó L; Morales JM; Oliver J; Guinea G;
Transplantation; 2011 Aug; 92(4):426-32. PubMed ID: 21760569
[TBL] [Abstract][Full Text] [Related]
22. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
23. Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.
Budde K; Glander P; Diekmann F; Dragun D; Waiser J; Fritsche L; Neumayer HH
Transplant Proc; 2004 Mar; 36(2 Suppl):524S-527S. PubMed ID: 15041401
[TBL] [Abstract][Full Text] [Related]
24. Sites of gastrointestinal lesion induced by mycophenolate mofetil: a comparison with enteric-coated mycophenolate sodium in rats.
Jia Y; Wang R; Li L; Zhang Y; Li J; Wang J; Wang X; Qi G; Rong R; Xu M; Zhu T
BMC Pharmacol Toxicol; 2018 Jul; 19(1):39. PubMed ID: 29973291
[TBL] [Abstract][Full Text] [Related]
25. Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic).
Budde K; Knoll G; Curtis J; Chan L; Pohanka E; Gentil M; Seifu Y; Marrast AC; Neumayer HH;
Clin Nephrol; 2006 Aug; 66(2):103-11. PubMed ID: 16939066
[TBL] [Abstract][Full Text] [Related]
26. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study.
Kobashigawa JA; Renlund DG; Gerosa G; Almenar L; Eisen HJ; Keogh AM; Lehmkuhl HB; Livi U; Ross H; Segovia J; Yonan N;
J Heart Lung Transplant; 2006 Aug; 25(8):935-41. PubMed ID: 16890114
[TBL] [Abstract][Full Text] [Related]
27. Estimation of Mycophenolic Acid Area Under the Curve With Limited-Sampling Strategy in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium.
Jia Y; Peng B; Li L; Wang J; Wang X; Qi G; Rong R; Wang L; Qiu J; Xu M; Zhu T
Ther Drug Monit; 2017 Feb; 39(1):29-36. PubMed ID: 27941535
[TBL] [Abstract][Full Text] [Related]
28. Enteric-coated mycophenolate sodium.
Budde K; Dürr M; Liefeldt L; Neumayer HH; Glander P
Expert Opin Drug Saf; 2010 Nov; 9(6):981-94. PubMed ID: 20795786
[TBL] [Abstract][Full Text] [Related]
29. Conversion from mycophenolate mofetil to delayed formulation in pediatric renal transplantation: higher mycophenolic acid predose level but no changes in the immune biomarkers.
Ferraris JR; Tambutti ML; Prigoshin N; Grosman M; Cardoni RL
Pediatr Transplant; 2009 Sep; 13(6):731-6. PubMed ID: 19497019
[TBL] [Abstract][Full Text] [Related]
30. The magnitude and time course of changes in mycophenolic acid 12-hour predose levels during antibiotic therapy in mycophenolate mofetil-based renal transplantation.
Borrows R; Chusney G; Loucaidou M; James A; Van Tromp J; Cairns T; Griffith M; Hakim N; McLean A; Palmer A; Papalois V; Taube D
Ther Drug Monit; 2007 Feb; 29(1):122-6. PubMed ID: 17304160
[TBL] [Abstract][Full Text] [Related]
31. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients.
Massari P; Duro-Garcia V; Girón F; Hernández E; Juárez F; Castro C; Toledo M;
Transplant Proc; 2005 Mar; 37(2):916-9. PubMed ID: 15848574
[TBL] [Abstract][Full Text] [Related]
32. Enteric-coated mycophenolate-sodium in heart transplantation: efficacy, safety, and pharmacokinetic compared with mycophenolate mofetil.
Lehmkuhl H; Hummel M; Kobashigawa J; Ladenburger S; Rothenburger M; Sack F; Dengler T; Hetzer R
Transplant Proc; 2008 May; 40(4):953-5. PubMed ID: 18555088
[TBL] [Abstract][Full Text] [Related]
33. Limited sampling strategies drawn within 3 hours postdose poorly predict mycophenolic acid area-under-the-curve after enteric-coated mycophenolate sodium.
de Winter BC; van Gelder T; Mathot RA; Glander P; Tedesco-Silva H; Hilbrands L; Budde K; van Hest RM
Ther Drug Monit; 2009 Oct; 31(5):585-91. PubMed ID: 19704401
[TBL] [Abstract][Full Text] [Related]
34. Enteric-coated mycophenolate sodium reduces gastrointestinal symptoms in renal transplant patients.
Burg M; Säemann MD; Wieser C; Kramer S; Fischer W; Lhotta K
Transplant Proc; 2009 Dec; 41(10):4159-64. PubMed ID: 20005359
[TBL] [Abstract][Full Text] [Related]
35. Absorption characteristics of EC-MPS--an enteric-coated formulation of mycophenolic sodium.
Arns W; Gies M; Choi L; Zhu W; Cooper P; Yeh CM; Prasad P; Graf P; Schmouder R
Int J Clin Pharmacol Ther; 2006 Aug; 44(8):375-85. PubMed ID: 16961168
[TBL] [Abstract][Full Text] [Related]
36. Effect of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium on maximum tolerated dose and gastrointestinal symptoms following kidney transplantation.
Shehata M; Bhandari S; Venkat-Raman G; Moore R; D'Souza R; Riad H; Bakran A; Baker R; Needham C; Andrews C
Transpl Int; 2009 Aug; 22(8):821-30. PubMed ID: 19386081
[TBL] [Abstract][Full Text] [Related]
37. Pharmacodynamic monitoring of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable kidney-allograft recipients.
Böhler T; Canivet C; Galvani S; Therville N; Salvayre R; Negre-Salvayre A; Durand D; Thomsen M; Rostaing L; Kamar N
Int Immunopharmacol; 2008 May; 8(5):769-73. PubMed ID: 18387521
[TBL] [Abstract][Full Text] [Related]
38. Mycophenolic acid formulation affects cyclosporine pharmacokinetics in stable kidney transplant recipients.
Cattaneo D; Merlini S; Baldelli S; Bartolini B; Nicastri A; Gotti E; Remuzzi G; Perico N
Ther Drug Monit; 2006 Oct; 28(5):643-9. PubMed ID: 17038879
[TBL] [Abstract][Full Text] [Related]
39. A possible simplification for the estimation of area under the curve (AUC₀₋₁₂) of enteric-coated mycophenolate sodium in renal transplant patients receiving tacrolimus.
Fleming DH; Mathew BS; Prasanna S; Annapandian VM; John GT
Ther Drug Monit; 2011 Apr; 33(2):165-70. PubMed ID: 21383656
[TBL] [Abstract][Full Text] [Related]
40. Best single time points to predict the area-under-the-curve in long-term heart transplant patients taking mycophenolate mofetil in combination with cyclosporine or tacrolimus.
Mardigyan V; Giannetti N; Cecere R; Besner JG; Cantarovich M
J Heart Lung Transplant; 2005 Oct; 24(10):1614-8. PubMed ID: 16210138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
